Ozempic News Fuels This Stock’s Big Move 🧬

Are you seeing this?!

October 30, 2024

LIVE in OUR House

Jeff hosts special guest - Pro Trader 📈, TV STAR🤩 and HEART-THROB💔- in the Market Master’s Room to talk EVERYTHING OPTIONS. 

I sure hope you caught my email this morning or caught my text messages…

If you slept through them – what were you doing?!  

I warned you to get ready last night and even to set that alarm to remind you, LOL.  

Anyways, I hope didn’t miss the chance to watch a real rocket ride 🚀 that may only be getting started.

If somehow, it slipped your mind – Now is the perfect time to start watching TLSA (not, Tesla, lol!)

This morning, I wrote that TLSA had “several standout features that I love to see,” not least of which was the incredible momentum it had picked up beginning last week.

I felt it could be ready for liftoff based on the price action alone…

But then I came across this incredible news drop:

That “nasal anti-CD3” is Foralumab, TLSA’s leading drug candidate, and the article covers the results of a potentially game-changing preclinical study.

Investors are going wild over the news so far:

The stock spiked as high as 20%, and as of this writing, it’s picking up momentum again as it made a fresh high of the day before lunchtime!

It’s now one of the top movers of the day for the entire market.

I think we could be in store for a way bigger day as more investors come across the news.

The study — conducted by Dr. Howard Weiner and Selma Boulenouar PhD, and a research team at Brigham and Women’s Hospital in Boston — found that “Nasal anti-CD3 in combination with semaglutide [Ozempic] demonstrates synergistic effects in promoting liver homeostasis in preclinical models of diet-induced obesity”

It also found that “The combination significantly reduces inflammation markers, a key factor in obesity-related metabolic disorders.”

As I’m sure you’ve heard, Ozempic is perhaps the hottest drug on the market right now, and this study suggests TLSA’s drug candidate may be a powerful complement to it.

Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

As the company explained:

In Figure 1, the far-right column shows the explanted liver and histology of that liver at two magnifications for a mouse fed a low-fat chow “normal” diet (“lean mouse”). The dark and smaller liver on the right is a typical healthy liver from a lean mouse. All the mice under the gray bar in the figure were fed a high fat chow (“HFD”) resulting in diet-induced obesity. As the columns outlined by red boxes demonstrate, administration of the combination of nasal anti-CD3 and semaglutide had livers that looked more like the liver from the lean mouse. The HFD mice given low dose or high dose semaglutide alone had enlarged fatty livers that were more similar to the HFD control.

Dr. Weiner noted that “This could pave the way for an entirely new approach in treating obesity-related metabolic disorders.”

If you slept on my alerts this morning, I sure hope you aren’t sleeping now…

TLSA is on the move and should be at the very top of your watchlist today.

To Your Success,

*Issuer Paid Content.  Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we were paid thirty thousand dollars directly from  Tiziana Life Sciences Ltd for a one day marketing program on October 30, 2024. Previously, we received seventeen thousand five hundred dollars (cash) from Interactive Offers for advertising Tiziana Life Sciences Ltd for a one day marketing program on June 6, 2024. Before that, we were paid seventeen thousand five hundred dollars (cash) from Interactive Offers for advertising Tiziana Life Sciences Ltd for a one day marketing program on April 22, 2024. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into  Tiziana Life Sciences Ltd might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry auth.ority, or any self-regulat0ry organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.